Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 604 trials

Laryngeal Cancer: ELOS Study on New Treatment

We are studying whether adding pembrolizumab to standard chemotherapy and radiation helps patients with advanced laryngeal cancer avoid laryngectomy. This trial also examines the impact on swallowing quality and overall survival.

Advanced Laryngeal and Hypopharyngeal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Advanced Cancer: AZD8205 Treatment Study

We are studying the safety and early effectiveness of AZD8205, both alone and with other cancer treatments, for people with advanced or metastatic solid tumors. This research aims to find the best dose and understand how the drug works in the body.

Breast CancerOvarian CancerEndometrial CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatology

Chemotherapy-Induced Polyneuropathy: Aconite Pain Oil Study

We are studying whether Aconite Pain Oil can help prevent and reduce symptoms of chemotherapy-induced polyneuropathy in cancer patients. The goal is to improve quality of life and manage symptoms during treatment.

Chemotherapy-Induced Polyneuropathy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyOncology

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ODM-212 Study

We are testing a new oral medication, ODM-212, in patients with advanced solid tumors to evaluate its safety and how well it may work. This study aims to find the best dose and understand its effects on tumor growth.

Neoplasms (Tumors)>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyPsychiatry

Type 2 Diabetes: BCAA Oxidation Study

We are investigating whether boosting branched-chain amino acid oxidation can lower blood sugar levels in people with type 2 diabetes. The study also examines effects on insulin sensitivity, heart health, and cognitive function.

Type 2 Diabetes6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDiabetologyEndocrinology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology